Replimune Reports Fiscal Second Quarter 2027 Financial Results
Replimune Group, Inc. announced its financial results for the fiscal second quarter ended September 30, 2026, and provided a corporate update.
Stocks · News reference
JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-10-28 AccNo: 0001104659-26-119354 Size: 272 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Replimune to Report Fiscal Second Quarter 2027 Financial Results on October 28, 2026
Replimune Group, Inc. has scheduled a conference call for October 28, 2026, to discuss its financial results for the fiscal second quarter ended September 30, 2026, and provide a corporate update.
Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
Mestag Therapeutics announced the appointment of Philip Astley-Sparke and Victor Sandor, M.D.C.M. to its Board of Directors. Both appointees bring extensive biotech and oncology development experience. The appointments strengthen the Board as Mestag advances MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody, in the Phase 1 STARLYS trial for patients with advanced solid tumors.